164 related articles for article (PubMed ID: 25367933)
1. PD-1 inhibitor approved for melanoma.
Cancer Discov; 2014 Nov; 4(11):1249. PubMed ID: 25367933
[No Abstract] [Full Text] [Related]
2. Programmed death protein 1 inhibitors making inroads in multiple cancers.
Brower V
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
[No Abstract] [Full Text] [Related]
3. Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.
Hamid O
Clin Adv Hematol Oncol; 2014 Nov; 12(11):782-4. PubMed ID: 25674719
[No Abstract] [Full Text] [Related]
4. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab: first global approval.
Poole RM
Drugs; 2014 Oct; 74(16):1973-1981. PubMed ID: 25331768
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
Harvey NT; Millward M; Macgregor K; Bucat RP; Wood BA
Am J Dermatopathol; 2016 Dec; 38(12):e159-e162. PubMed ID: 27870733
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.
van der Kooij MK; Joosse A; Speetjens FM; Hospers GA; Bisschop C; de Groot JW; Koornstra R; Blank CU; Kapiteijn E
Acta Oncol; 2017 Jan; 56(1):101-103. PubMed ID: 27911126
[No Abstract] [Full Text] [Related]
11. PD-1 inhibitors effective in hodgkin lymphoma.
Cancer Discov; 2015 Feb; 5(2):102-3. PubMed ID: 25656882
[No Abstract] [Full Text] [Related]
12. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
13. Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1.
Thomas S; Laino A; Sturm R; Nufer K; Lambie D; Shepherd B; Atkinson V; Adams L; Soyer HP; Schaider H
J Eur Acad Dermatol Venereol; 2018 May; 32(5):e176-e177. PubMed ID: 29114959
[No Abstract] [Full Text] [Related]
14. American Association of Cancer Research Showcases Immunotherapy Advances.
Brower V
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
[No Abstract] [Full Text] [Related]
15. Toripalimab: First Global Approval.
Keam SJ
Drugs; 2019 Apr; 79(5):573-578. PubMed ID: 30805896
[TBL] [Abstract][Full Text] [Related]
16. Scleroderma Induced by Pembrolizumab: A Case Series.
Barbosa NS; Wetter DA; Wieland CN; Shenoy NK; Markovic SN; Thanarajasingam U
Mayo Clin Proc; 2017 Jul; 92(7):1158-1163. PubMed ID: 28599746
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of metastatic mucosal melanoma with a Del579 c-KIT mutation by imatinib after treatment of anti-PD-1 antibody.
Yamashita C; Otsuka A; Nomura M; Honda T; Kabashima K
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e92-e93. PubMed ID: 30199578
[No Abstract] [Full Text] [Related]
18. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
[No Abstract] [Full Text] [Related]
19. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
Maul LV; Weichenthal M; Kähler KC; Hauschild A
J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
[TBL] [Abstract][Full Text] [Related]
20. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Hugo W; Zaretsky JM; Sun L; Song C; Moreno BH; Hu-Lieskovan S; Berent-Maoz B; Pang J; Chmielowski B; Cherry G; Seja E; Lomeli S; Kong X; Kelley MC; Sosman JA; Johnson DB; Ribas A; Lo RS
Cell; 2016 Mar; 165(1):35-44. PubMed ID: 26997480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]